Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703)

This study has been terminated.
(voluntary)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by:
Duke University
ClinicalTrials.gov Identifier:
NCT00545948
First received: October 16, 2007
Last updated: February 3, 2011
Last verified: February 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: June 2013
  Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)